Gelonghui August 4th 丨Shanghai Pharmaceutical (02607.HK) announced that recently, the company's holding subsidiary Changzhou Pharmaceutical Co., Ltd. (hereinafter referred to as “Changzhou Pharmaceutical Factory”) of its holding subsidiary, Changzhou Pharmaceutical Co., Ltd. (hereinafter referred to as “Changzhou Pharmaceutical Factory”), received the “Drug Supplement Application Approval Notice” (Notice number: 2022B03108) issued by the China Drug Administration (hereinafter referred to as “China Drug Administration”). The drug was the first in China to pass a consistent evaluation of the quality and efficacy of generic drugs.